The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
In this video, Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, comments on two notable topics in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) from EHA 2026, including the development of secondary myeloid malignancies post CAR T-cell therapy and the potential of menin inhibitors in treating these malignancies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I found two topics very interesting for me from my point of view. The first one is regarding secondary myeloid malignancy post CAR T-cells. So actually you are treating patients with CAR T-cells for lymphoid malignancy and they can develop, some of them develop myeloid malignancies secondary so the conclusion of this presentation was usually there is some predisposition with gene mutation on those patients you know so they develop this myeloid after CAR-T I would say yes, I agree with this hypothesis, but for me, it’s not enough because you can have this predisposition mutations, but you never develop MDS or acute leukemia, for instance...
I found two topics very interesting for me from my point of view. The first one is regarding secondary myeloid malignancy post CAR T-cells. So actually you are treating patients with CAR T-cells for lymphoid malignancy and they can develop, some of them develop myeloid malignancies secondary so the conclusion of this presentation was usually there is some predisposition with gene mutation on those patients you know so they develop this myeloid after CAR-T I would say yes, I agree with this hypothesis, but for me, it’s not enough because you can have this predisposition mutations, but you never develop MDS or acute leukemia, for instance. But my hypothesis is really this is a cytokine matter you know so if I have an advice for the younger researchers you know around Europe because now in Europe it’s really to focus on the role of the cytokine and the genesis of leukemia this is very important and we all know after CAR T-cells, so there will be some cytokine storms or some imbalance in the cytokine equilibrium. So it can be the key to understand this. This is very important. And now we are opening the era of in vivo CAR-T, which is something very attractive, I would say, but we need to be aware regarding this complication, you know, because we cannot control everything and we need really to work on this cytokine matter. The second topic, it’s really far from this, but the treatment with menin inhibitors, you know. So nowadays we have more and more publications or communication regarding these menin inhibitors. So for now, a small number of patients can benefit from this, but I think we need to think about enlarging the indication and using some combination so that we can bring something new to the treatment of MDS and AML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
